A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea

Completed · Not applicable · Has a placebo group

Conditions studied: Rosacea

In brief

This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild to moderate rosacea.

Key facts

Study ID

NCT01740934

Run by

Rock Creek Pharmaceuticals, Inc.

People needed

117

Starts

2012-11-01

Expected to finish

2013-08-01

Last updated by the study team

2015-11-02

Who can join

Age: 25 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age between 25-70 years
• diagnosed with mild to moderate rosacea

You may not qualify if…

• allergy or sensitivity to the study products or their components
• severe rosacea
• current use of glucocorticoids, anti-acne products, antibiotics, topical retinoids, or vasoactive drugs
• recent oral isotretinoin use
• current use of anatabine-containing supplements (ie. Anatabloc, Anatabloc Unflavored, CigRx)

Where it is running

• Susan H. Weinkle, MD — Bradenton, Florida, United States
• Lupo Center for Aesthetic & General Dermatology — New Orleans, Louisiana, United States
• Diane Berson, MD — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.